

Express Mail Label: EV058075736U  
Date of Deposit: May 16, 2002

Attorney Docket No.: 15966-585 CIP2 (Cura-85CIP2)

05-17-02  
6P 1653  
RECEIVED

MAY 21 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Prayaga et al.

SERIAL NUMBER : 09/973,424

EXAMINER : Not Yet Assigned

FILING DATE : October 9, 2001

ART UNIT : 1653

FOR : Novel Polypeptides Homologous to Thymosin, Ephrin A Receptors, and  
Fibromodulin and Polynucleotides Encoding Same



Commissioner for Patents  
Washington, D.C. 20231



30623

PATENT TRADEMARK OFFICE

TRANSMITTAL LETTER


Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (2 pages), in duplicate; and
3. Return Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 15966-585 CIP2 (Cura-85 CIP2). A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

  
Ivor R. Elrifi, Reg. No. 39,529  
Attorney for Applicants  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Dated: May 16, 2002

TRA 1668533v1

Express Mail Label No.: EV0580757/US  
Date of Deposit: May 16, 2002

Attorney Docket No.: 15966-585 CIP2 (Cura-85 CIP2)



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Prayaga et al.  
SERIAL NUMBER: 09/973,424  
FILING DATE: October 9, 2001  
FOR: Novel Polypeptides Homologous to Thymosin, Ephrin A Receptors, and Fibromodulin, and Polynucleotides Encoding Same

EXAMINER: Not Yet Assigned  
ART UNIT: 1653

RECEIVED  
MAY 21 2002  
TECH CENTER 1600/2900

**BOX IDS**

Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of the first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANTS: Prayaga et al.  
U.S.S.N.: 09/973,424

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 15966-585 CIP2 (Cura-85 CIP2).

Respectfully submitted,


  
Ivor R. Elrifi, Reg. No. 39,529  
Attorney for Applicant  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Dated: May 16, 2002

TRA 1667952v1

Express Mail No.: EV058075736US  
Date of Deposit: May 16, 2002

Please type a plus sign (+) in this box



RECEIVED

MAY 21 2002

Page 1 of 2

TECH CENTER 1600/2900

Approved for use through 9/30/00. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Modified Form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	09/973,424
	<b>Filing Date</b>	10/09/01
	<b>First Named Inventor</b>	Prayaga
	<b>Group Art Unit</b>	1653
	<b>Examiner Name</b>	Not Assigned
	<b>Attorney Docket Number</b>	15966-585 CIP2(Cura-85 CIP2)


U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B1*	WO	99/47674	Corixa Corp.	09/23/1999		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1*	Abdollahi et al. (1991). "Sequence and expression of a cDNA encoding MyD118: a novel myeloid differentiation primary response gene induced by multiple cytokines." <u>Oncogene</u> 6(1): 165-167.
	C2*	Aumailley and Gayraud (1998). "Structure and biological activity of the extracellular matrix." <u>J Mol Med</u> 76(3-4): 253-265.
	C3*	Bodey et al. (2000). "Review of thymic hormones in cancer diagnosis and treatment." <u>Int J Immunopharmacol</u> 22(4): 261-273.
	C4*	Bruckner-Tuderman and Bruckner (1998). "Genetic diseases of the extracellular matrix: more than just connective tissue disorders." <u>J Mol Med</u> 76(3-4): 226-237.
	C5*	GenBank Accession Number: <b>X59292</b> (01/21/99)
	C6*	GenBank Accession Number: <b>NP_065387</b> (11/02/00)
	C7*	Chan and Watt (1991). "eek and erk, new members of the eph subclass of receptor protein- tyrosine kinases." <u>Oncogene</u> 6(6): 1057-1061.
	C8*	Choi et al. (1999). "Characterization of ephrin-A1 and ephrin-A4 as ligands for the EphA8 receptor protein tyrosine kinase." <u>Mol Cells</u> 9(4): 440-445.
	C9*	Frisen et al. (1999). "Ephrins and their Eph receptors: multitalented directors of embryonic development." <u>Embo J</u> 18(19): 5159-5165.
	C10*	Hall (1995). "Thymosin beta-10 accelerates apoptosis." <u>Cell Mol Biol Res</u> 41(3): 167-180.
	C11*	Lacy et al. (1999). "Identification of FLRT1, FLRT2, and FLRT3: a novel family of transmembrane leucine-rich repeat proteins." <u>Genomics</u> 62(3): 417-426.
	C12*	Lin and Morrison-Bogorad (1991). "Cloning and characterization of a testis-specific thymosin beta 10 cDNA. Expression in post-meiotic male germ cells." <u>J Biol Chem</u> 266(34): 23347-23353.
	C13*	Muallem et al. (1995). "Actin filament disassembly is a sufficient final trigger for exocytosis in nonexcitable cells." <u>J Cell Biol</u> 128(4): 589-598.
	C14*	Genbank Accession Number: <b>O09127</b> (05/30/00)
	C15*	Santelli et al. (1999). "Thymosin beta-10 gene overexpression is a general event in human carcinogenesis." <u>Am J Pathol</u> 155(3): 799-804.
	C16*	Sztrolovics et al. (1999). "Resistance of small leucine-rich repeat proteoglycans to proteolytic

Express Mail No.: EV058075736US  
Date of Deposit: May 16, 2002

Page 2 of 2



OTHER PRIOR ART AND PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
		degradation during interleukin-1-stimulated cartilage catabolism." <i>Biochem J</i> 339(Pt 3): 571-577.
	C17*	Sztrolovics et al. (1994). "Localization of the human fibromodulin gene (FMOD) to chromosome 1q32 and completion of the cDNA sequence." <i>Genomics</i> 23(3): 715-717.
	C18*	Wang et al. (1998). "Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4 [see comments]." <i>Cell</i> 93(5): 741-753.
	C19*	EMBL Database Accession Number: <b>Z93023</b> (03/19/97).
	C20*	EMBL Database Accession Number: <b>AA758513</b> (01/26/98).
	C21*	EMBL Database Accession Number: <b>AL035703</b> (03/12/99).
	C22*	EMBL Database Accession Number: <b>U72207</b> (12/25/96).
	C23*	EMBL Database Accession Number: <b>AB040892</b> (05/23/00).
	C24*	EMBL Database Accession Number: <b>AF007139</b> (02/09/98).
	C25*	EMBL Database Accession Number: <b>AF169675</b> (01/31/00).
	C26*	EMBL Database Accession Number: <b>AP000597</b> (10/15/99).
	C27*	Nagase et al. (2000). <i>DNA Res.</i> 7: 143-150.
	C28*	Park and Sanchez (1997). <i>Oncogene</i> 14: 533-542.
	C29*	Tureci, et al. (1998). <i>Proc. Natl. Acad. Sci. USA</i> 95: 7608-7613.
	C30*	Weternan, et al. (1993). <i>Int. J. Cancer</i> 53: 278-284.
	C31*	International Search Report for PCT/US 00/28474. Mailed on July 5, 2001.

RECEIVED

MAY 21 2002

TECH CENTER 1600/2900

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/689,486, filed **October 12, 2000**, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.